kinetoplastid-selective proteasome inhibitor
oral antileishmanial in Ph. I in HV
From 3M cmpd antiprolif. screen + opt.
J. Med. Chem., Jul. 29, 2020
Novartis (GNF), San Diego, CA
LXE408
LXE408 is an oral antileishmanarial compound that selectively targets the kinetoplastid proteosome vs. the mammalian proteosome. The prior candidate, GNF6702, had solubility-limited oral absorption, which could have been addressed with…